Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
The clinical, immunologic, and virologic effects and the pharmacokinetics of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin (HIVIG) were assessed in 30 HIV-infected children aged 2-11 years. All had moderately advanced disease with an immune complex-dissociated (ICD) p24 antigen >70 pg/mL and were on stable antiviral therapy. Three groups of 10 children received 6 monthly infusions of 200, 400, or 800 mg/kg of HIVIG, and serial immunologic and virologic assays were performed. HIVIG doses as high as 800 mg/kg were safe and well tolerated. The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6-6.0 mL/kg/day. Plasma ICD p24 decreased during the infusions, but CD4 cell levels, plasma RNA copy number, cellular virus, immunoglobulin levels, and neutralizing antibody titers were minimally affected by the infusions. Clinical status did not change during the 6-month infusion and 3-month follow-up periods.
Stiehm
E R
ER
UCLA Children's Hospital, Los Angeles, CA 90095, USA. estiehm@mednet. ucla.edu
Fletcher
C V
CV
Mofenson
L M
LM
Palumbo
P E
PE
Kang
M
M
Fenton
T
T
Sapan
C V
CV
Meyer
W A
WA
Shearer
W T
WT
Hawkins
E
E
Fowler
M G
MG
Bouquin
P
P
Purdue
L
L
Sloand
E M
EM
Nemo
G J
GJ
Wara
D
D
Bryson
Y J
YJ
Starr
S E
SE
Petru
A
A
Burchett
S
S
D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D005260:Female; D015483:HIV Antibodies / Q000276:immunology*; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000276:immunology / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear; D018655:Lymphocyte Count; D008297:Male; D009500:Neutralization Tests; D012367:RNA, Viral / Q000097:blood; D016176:T-Lymphocyte Subsets / Q000276:immunology; D016896:Treatment Outcome
D015483:HIV Antibodies; D016655:HIV Core Protein p24; C084715:HIV hyperimmune globulin; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D012367:RNA, Viral